Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease

R. Yarchoan, R. V. Thomas, J. Grafman, A. Wichman, M. Dalakas, N. McAtee, G. Berg, Margaret A Fischl, C. F. Perno, R. W. Klecker, A. Buchbinder, S. Tay, S. M. Larson, C. E. Myers, S. Broder

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus-associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.

Original languageEnglish
JournalAnnals of Neurology
Volume23
Issue numberSUPPL.
StatePublished - Jan 1 1988

Fingerprint

Zidovudine
Acquired Immunodeficiency Syndrome
Peripheral Nervous System Diseases
Dementia
HIV
Paraplegia
Neural Conduction
Electrons
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Yarchoan, R., Thomas, R. V., Grafman, J., Wichman, A., Dalakas, M., McAtee, N., ... Broder, S. (1988). Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. Annals of Neurology, 23(SUPPL.).

Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. / Yarchoan, R.; Thomas, R. V.; Grafman, J.; Wichman, A.; Dalakas, M.; McAtee, N.; Berg, G.; Fischl, Margaret A; Perno, C. F.; Klecker, R. W.; Buchbinder, A.; Tay, S.; Larson, S. M.; Myers, C. E.; Broder, S.

In: Annals of Neurology, Vol. 23, No. SUPPL., 01.01.1988.

Research output: Contribution to journalArticle

Yarchoan, R, Thomas, RV, Grafman, J, Wichman, A, Dalakas, M, McAtee, N, Berg, G, Fischl, MA, Perno, CF, Klecker, RW, Buchbinder, A, Tay, S, Larson, SM, Myers, CE & Broder, S 1988, 'Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease', Annals of Neurology, vol. 23, no. SUPPL..
Yarchoan R, Thomas RV, Grafman J, Wichman A, Dalakas M, McAtee N et al. Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. Annals of Neurology. 1988 Jan 1;23(SUPPL.).
Yarchoan, R. ; Thomas, R. V. ; Grafman, J. ; Wichman, A. ; Dalakas, M. ; McAtee, N. ; Berg, G. ; Fischl, Margaret A ; Perno, C. F. ; Klecker, R. W. ; Buchbinder, A. ; Tay, S. ; Larson, S. M. ; Myers, C. E. ; Broder, S. / Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease. In: Annals of Neurology. 1988 ; Vol. 23, No. SUPPL.
@article{def58c8d46584cd69d22fa1862fd09a1,
title = "Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease",
abstract = "3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus-associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.",
author = "R. Yarchoan and Thomas, {R. V.} and J. Grafman and A. Wichman and M. Dalakas and N. McAtee and G. Berg and Fischl, {Margaret A} and Perno, {C. F.} and Klecker, {R. W.} and A. Buchbinder and S. Tay and Larson, {S. M.} and Myers, {C. E.} and S. Broder",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "23",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "SUPPL.",

}

TY - JOUR

T1 - Long-term administration of 3'-azido-2',3'-dideoxythymidine to patients with AIDS-related neurological disease

AU - Yarchoan, R.

AU - Thomas, R. V.

AU - Grafman, J.

AU - Wichman, A.

AU - Dalakas, M.

AU - McAtee, N.

AU - Berg, G.

AU - Fischl, Margaret A

AU - Perno, C. F.

AU - Klecker, R. W.

AU - Buchbinder, A.

AU - Tay, S.

AU - Larson, S. M.

AU - Myers, C. E.

AU - Broder, S.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - 3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus-associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.

AB - 3'-Azido-2',3'-dideoxythymidine (AZT) has been administered to 7 patients with human immunodeficiency virus-associated neurological disease: 3 with dementia, 2 with peripheral neuropathy, 1 with dementia and peripheral neuropathy, and 1 with T-10 paraplegia. Six of the patients showed improvement in their neurological dysfunction on being administered AZT, as assessed by clinical evaluation, neuropsychological testing, nerve conduction studies, and/or positron emission tomographic scans. Three of these 6 patients showed sustained improvement 5 to 18 months after the initiation of AZT therapy. These results suggest that certain human immunodeficiency virus-associated neurological abnormalities are at least partially reversible following the administration of antiretroviral therapy and provide a rationale for further studies using antiretroviral chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0023712221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023712221&partnerID=8YFLogxK

M3 - Article

VL - 23

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - SUPPL.

ER -